EBS
Emergent Biosolutions Inc
6.70$
-1.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.3% | +8.6% | -15.2% | +15.4% | -33.7% | +14.1% | -36.6% | +64.0% | -35.7% | +5.0% | +50.1% | – | |
| – | -39.7% | +48.6% | +100.6% | -59.5% | -55.1% | +81.6% | -21.1% | +22.3% | +0.1% | -13.3% | +9.7% | – | |
| – | +83.1% | -16.8% | -146.5% | – | -16.9% | -14.7% | -50.6% | +124.5% | -63.9% | +45.1% | +103.0% | – | |
| – | +92.2% | -48.6% | +116.6% | -57.8% | -34.1% | +67.0% | -14.5% | +3.8% | -10.4% | -13.2% | -12.4% | – | |
| – | +4.3% | -5.6% | +1.4% | -10.8% | -20.6% | -13.8% | -16.6% | -11.0% | +31.4% | -8.8% | -4.3% | – | |
| – | -36.3% | -52.6% | +36.6% | -27.8% | +46.4% | -53.5% | -16.1% | -8.2% | +20.8% | -9.7% | +359.4% | – | |
| – | – | – | -611.3% | – | -114.7% | – | -99.0% | +15,260.0% | -121.6% | – | -1,291.4% | – | |
| – | +12.7% | +9.5% | -2.9% | -64.8% | +78.3% | -0.7% | +0.0% | +3.4% | -3.3% | -25.2% | -9.1% | – | |
| – | – | – | -2,329.8% | – | -119.4% | – | -118.1% | – | -188.0% | – | -1,341.0% | – | |
| – | – | – | +329.0% | +107.5% | -86.6% | +567.6% | -119.4% | – | -39.1% | +69.2% | +110.6% | – | |
| – | – | – | -3,245.6% | – | -127.3% | – | -117.6% | – | -206.6% | – | -2,750.0% | – | |
| – | -157.9% | – | -307.4% | – | -78.5% | +535.2% | -83.6% | +341.1% | -112.9% | – | -422.3% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.